A5103257692- Hepatitis C virus research
- Liver Disease Diagnosis and Treatment
- Hepatitis B Virus Studies
- Liver Disease and Transplantation
- Systemic Lupus Erythematosus Research
- Hepatitis Viruses Studies and Epidemiology
- HIV/AIDS drug development and treatment
- Alcohol Consumption and Health Effects
- Microbial metabolism and enzyme function
- Drug-Induced Hepatotoxicity and Protection
- Organ Transplantation Techniques and Outcomes
- Hepatocellular Carcinoma Treatment and Prognosis
- Travel-related health issues
- Liver Diseases and Immunity
- HIV, Drug Use, Sexual Risk
- Chronic Lymphocytic Leukemia Research
- Heparin-Induced Thrombocytopenia and Thrombosis
- Liver physiology and pathology
- Vascular Tumors and Angiosarcomas
- PI3K/AKT/mTOR signaling in cancer
- Lipid metabolism and disorders
- Substance Abuse Treatment and Outcomes
- Ethics and Social Impacts of AI
- Telemedicine and Telehealth Implementation
- Cardiac, Anesthesia and Surgical Outcomes
Marqués de Valdecilla University Hospital
2014-2024
Instituto de Investigación Marqués de Valdecilla
2015-2024
Universidad de Cantabria
2016-2020
Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas
2017-2018
Creative Research Enterprises (United States)
2015-2018
Hospital General Universitario Gregorio Marañón
2018
Instituto de Salud Carlos III
2018
Universitat Autònoma de Barcelona
2018
Hospital Clínic de Barcelona
2017
Universitat de Barcelona
2017
Abstract Epigenetic modifications such as DNA and histone methylation functionally cooperate in fostering tumor growth, including that of hepatocellular carcinoma (HCC). Pharmacological targeting these mechanisms may open new therapeutic avenues. We aimed to determine the efficacy potential mechanism action our dual G9a histone‐methyltransferase DNA‐methyltransferase 1 (DNMT1) inhibitor human HCC cells their crosstalk with fibrogenic cells. The expression DNMT1 , along molecular adaptor...
Prisons are major reservoirs of hepatitis C virus (HCV) in which a therapeutic approach has been particularly difficult so far. Our aim was to create permanent program HCV elimination prison based on "test and treat" strategy.This open-label clinical trial conducted the Spanish "El Dueso" between May 2016 July 2017. Viremic patients were treated with ledipasvir-sofosbuvir regimen (8-12 weeks) according 2015 Guidelines. A teleconsultation established follow-up from hospital. Non-responders...
Accurate HCV prevalence estimates are necessary for guiding elimination policies. Our aim was to determine the and assess cost-effectiveness of a screen-and-treat strategy in Spanish population. A population-based, cross-sectional study (PREVHEP-ETHON Cohort, Epidemiological sTudy Hepatic infectiONs; NCT02749864) performed from July 2015-April 2017. Participants three regions were selected using two-stage conglomerate sampling, stratified by age, with randomized subject selection....
Summary Patients with HCV genotype 3 (GT3) infection and cirrhosis are currently the most difficult to cure. We report our experience sofosbuvir+daclatasvir (SOF+DCV) or sofosbuvir/ledipasvir (SOF/LDV), without ribavirin (RBV) in clinical practice this population. This was a multicenter observational study including cirrhotic patients infected by GT3, treated sofosbuvir plus an NS5A inhibitor (May 2014‐October 2015). In total, 208 were included: 98 (47%) treatment‐experienced, 42 (20%)...
Current evidence suggests that gut dysbiosis drives obesity and non-alcoholic fatty liver disease (NAFLD) pathogenesis. Toll-like receptor 2 (TLR2) TLR6 specifically recognize components of Gram-positive bacteria. Despite the potential implications TLR2 in NAFLD pathogenesis, role has not been addressed. Our aim is to study a obesity-related NAFLD. Forty morbidly obese patients undergoing bariatric surgery were prospectively studied. Cell surface expression was assessed on peripheral blood...
The Spanish prison population includes two groups: people in and those who are serving non-custodial sentences. latter has not yet been studied. This study aims to describe this the results of a test-and-treat strategy for hepatitis C including holistic health assessment.
Summary Background Sofosbuvir, velpatasvir and voxilaprevir (SOF/VEL/VOX) is the recommended rescue therapy for patients with chronic hepatitis C infection who fail direct‐acting antivirals (DAAs). Data are limited on effectiveness of this treatment after current first‐line therapies. Our aim was to analyse safety SOF/VEL/VOX among failing sofosbuvir/velpatasvir (SOF/VEL) or glecaprevir/pibrentasvir (GLE/PIB). Methods Retrospective multicentre study (26 Spanish hospitals), including...
Interferon-free therapies have an improved safety and efficacy profile. However, data in elderly patients, who frequently advanced liver disease, associated comorbidities, use concomitant medications are scarce. The im of this study was to assess the effectiveness tolerability all-oral regimens patients real-life clinical practice.Retrospective analysis hepatitis C virus (HCV) aged ≥65 years receiving interferon-free within Spanish National Registry (Hepa-C).Data 1,252 were recorded. Of...
Hepatitis C virus (HCV) is 15 times more prevalent among persons in Spain's prisons than the community. Recently, Spain initiated a pilot program, JAILFREE-C, to treat HCV using direct-acting antivirals (DAAs). Our aim was identify cost-effective strategy scale-up treatment all prisons. Using validated agent-based model, we simulated landscape considering disease transmission, screening, treatment, and prison-community dynamics. Costs outcomes under status quo were compared with strategies...
Summary In randomized controlled trials of patients with chronic HCV infection, elbasvir/grazoprevir ( EBR / GZR ) demonstrated high cure rates and a good safety profile. This study assessed the effectiveness , without ribavirin, in real‐world patient cohort. HEPA ‐C is collaborative, monitored national registry directed by Spanish Association for Study Liver Networked Biomedical Research Centre Hepatic Digestive Diseases. Patients entered into between December 2016 May 2017, treated at...
The latest epidemiological data in Spain were obtained a decade ago and revealed prevalence of hepatitis B surface antigen (HBsAg) 0.7%; hence, updated are necessary. Our aim was to determine the virus (HBV) infection, analyse associated factors characterize chronic infection. A population-based, cross-sectional study performed between July 2015 April 2017. Participants from three regions selected using two-stage conglomerate sampling stratified by age. Anthropometric demographic collected,...
El virus de la hepatitis C (VHC) es una las principales causas morbilidad y mortalidad relacionadas con el higado en todo mundo, mas 70 millones personas afectadas. Aproximadamente, entre 55 % 85 infectadas desarrollaran infeccion cronica por VHC 15 30 este grupo cirrosis hepatica complicaciones asociadas los 20-30 anos siguientes. En nuestro pais, seroprevalencia anti-VHC oscila 0,8 1,2 poblacion adulta, mientras que 0,2 0,4 muestran activa VHC. ultimos anos, gracias a aparicion agentes...
Introduction: the goal of this study was to determine prevalence hepatitis C virus (HCV) infection in patients with non-affective psychotic disorders and compare it population-based data.Material methods: an observational performed that measured anti-HCV antibodies (HCV-RNA case seropositivity) 425 serum samples from psychosis.Eight were positive for (1.9 %) five had detectable HCV-RNA (1.2 %).The viremia significantly higher than general population (OR: 5.4; 95 % CI: 1.9-14.6).Conclusions:...